Carla Lopes

Prof. Carla Lopes

Universidade Federal de São Paulo - UNIFESP

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
JOJessica Onyeisi
Jessica Onyeisi
CLCarla Lopes
Carla Lopes
Martin GötteMartin Götte
Martin Götte
Cancer is an important cause of morbidity and mortality worldwide. Advances in research on the biology of cancer revealed alterations in several key pathways underlying tumorigenesis and provided molecular targets for developing new and improved existing therapies. Syndecan-4, a transmembrane heparan sulfate proteoglycan, is a central mediator of cell adhesion, migration and proliferation. Although several studies have demonstrated important roles of syndecan-4 in cell behavior and its interactions with growth factors, extracellular matrix (ECM) molecules and cytoskeletal signaling proteins, less is known about its role and expression in multiple cancer. The data summarized in this review demonstrate that high expression of syndecan-4 is an unfavorable biomarker for estrogen receptor-negative breast cancer, glioma, liver cancer, melanoma, osteosarcoma, papillary thyroid carcinoma and testicular, kidney and bladder cancer. In contrast, in neuroblastoma and colorectal cancer, syndecan-4 is downregulated. Interestingly, syndecan-4 expression is modulated by anticancer drugs. It is upregulated upon treatment with zoledronate and this effect reduces invasion of breast cancer cells. In our recent work, we demonstrated that the syndecan-4 level was reduced after trastuzumab treatment. Similarly, syndecan-4 levels are also reduced after panitumumab treatment. Together, the data found suggest that syndecan-4 level is crucial for understanding the changes involving in malignant transformation, and also demonstrate that syndecan-4 emerges as an important target for cancer therapy and diagnosis.

1 April 2004 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
HNHelena B. Nader
Helena B. Nader
CLCarla Lopes
Carla Lopes
Hugo Alexandre Oliveira RochaHugo Alexandre Oliveira Rocha
Hugo Alexandre Oliveira Rocha
ESElizeu A. Santos
Elizeu A. Santos
CDCarl P. Dietrich
Carl P. Dietrich
The correlation between structure, anticloting, antithrombotic and hemorrhagic activities of heparin, heparan sulfate, low molecular weight heparins and heparin-like compounds from various sources that are in used in clinical practice or under development is briefly reviewed. Heparin-like molecules composed exclusively of iduronic acid 2-O-sulfate residues have weak anticloting activities, whereas molecules that contain both iduronic acid 2-O sulfate, iduronic acid and small amounts of glucuronic acid, such as heparin, or mixed amounts of glucuronic and iduronic acids (mollusk heparins) possess high anticloting and anti-Xa activities. These results also suggest that a proper combination of these elements might produce a strong antithrombotic agent. Heparin isolated from shrimp mimics the pharmacological activities of low molecular weight heparins. A heparan sulfate derived from bovine pancreas and a sulfated fucan from brown algae have a potent antithrombotic activity in arterial and venous thrombosis model “in vivo” with a negligible activity upon the serine-proteases of the coagulation cascade “in vitro”. These and other results led to the hypothesis that antithrombotic activity of heparin and other antithrombotic agents is due at least in part by their action on endothelial cells stimulating the synthesis of an antithrombotic heparan sulfate. All the antithrombotic agents derived from heparin and other heparinoids have hemorrhagic activity. Exceptions to this are a heparan sulfate from bovine pancreas and a sulfated fucan derived from brown algae, which have no hemorrhagic activity but have high antithrombotic activities “in vivo”. Once the structure of these compounds are totally defined it will be possible to design an ideal antithrombotic.

26 June 2017 in Apoptosis
Verified
Journal Article
Closed access
PDF file
AMAna Paula de Sousa Mesquita
Ana Paula de Sousa Mesquita
SLSilvana de Araújo Lopes
Silvana de Araújo Lopes
PFPaulo Castanho A. Pernambuco Filho
Paulo Castanho A. Pernambuco Filho
HNHelena B. Nader
Helena B. Nader
CLCarla Lopes
Carla Lopes

1 February 2006 in Brazilian Journal of Medical and Biological Research
Verified
Journal Article
Open access
PDF file
CLCarla Lopes
Carla Lopes
CDC.P. Dietrich
C.P. Dietrich
HNH.B. Nader
H.B. Nader
The syndecans, heparan sulfate proteoglycans, are abundant molecules associated with the cell surface and extracellular matrix and consist of a protein core to which heparan sulfate chains are covalently attached. Each of the syndecan core proteins has a short cytoplasmic domain that binds cytosolic regulatory factors. The syndecans also contain highly conserved transmembrane domains and extracellular domains for which important activities are becoming known. These protein domains locate the syndecan on cell surface sites during development and tumor formation where they interact with other receptors to regulate signaling and cytoskeletal organization. The functions of cell surface heparan sulfate proteoglycan have been centered on the role of heparan sulfate chains, located on the outer side of the cell surface, in the binding of a wide array of ligands, including extracellular matrix proteins and soluble growth factors. More recently, the core proteins of the syndecan family transmembrane proteoglycans have also been shown to be involved in cell signaling through interaction with integrins and tyrosine kinase receptors.

1 November 2017 in Matrix Biology
Verified
Journal Article
Closed access
RCR.P. Cavalheiro
R.P. Cavalheiro
MLM.A. Lima
M.A. Lima
TJT.R. Jarrouge-Bouças
T.R. Jarrouge-Bouças
GVG.M. Viana
G.M. Viana
CLCarla Lopes
Carla Lopes
HNHelena B. Nader
Helena B. Nader

12 November 2020 in Cancer Biology & Therapy
Verified
Journal Article
Closed access
JOJessica Onyeisi
Jessica Onyeisi
BFBianca Zaia Franco Ferreira
Bianca Zaia Franco Ferreira
HNHelena Bonciani Nader
Helena Bonciani Nader
CLCarla Lopes
Carla Lopes
Heparan sulfate proteoglycans (HSPGs) play important roles in cancer initiation and progression, by interacting with the signaling pathways that affect proliferation, adhesion, invasion and angiogenesis. These roles suggest the possibility of various strategies of regulation of these molecules. In this review, we demonstrated that the anticancer drugs can regulate the heparan sulfate proteoglycans activity in different ways: some act directly in core protein, and can bind to a specific type of HSPG. Others drugs interact with glycosaminoglycans chains, and others can act directly in enzymes that regulate HSPGs levels. We also demonstrated that the HSPGs drug targets can be divided into four groups: monoclonal antibodies, antitumor antibiotic, natural products, and mimetics peptide. Interestingly, many drugs demonstrated in this review are approved by FDA and is used in cancer therapy (Food and Drug Administration) like trastuzumab, panitumumab, bleomycin and bisphosphonate zoledronic acid (ASCO) or are in clinical trials like codrituzumab and genistein. This review should help researchers to understand the mechanism of action of anticancer drugs existing and also may inspire the discovery of new drugs that regulate the heparan sulfate proteoglycans activity. ABSTRACT